» Articles » PMID: 24866863

Comparison of a Closed System to a Standard Open Technique for Preparing Tissue-engineered Vascular Grafts

Abstract

We developed a prototype for a closed apparatus for assembling tissue-engineered vascular grafts (TEVGs) with the goal of creating a simple operator-independent method for making TEVGs to optimize safety and enable widespread application of this technology. The TEVG is made by seeding autologous bone marrow-derived mononuclear cells onto a biodegradable tubular scaffold and is the first man-made vascular graft to be successfully used in humans. A critical barrier, which has prevented the widespread clinical adoption of the TEVG, is that cell isolation, scaffold seeding, and incubation are performed using an open method. To reduce the risk of contamination, the TEVG is assembled in a clean room. Clean rooms are expensive to build, complex to operate, and are not available in most hospitals. In this investigation, we used an ovine model to compare the safety and efficacy of TEVGs created using either a standard density centrifugation-based open method or the new filter-based closed system. We demonstrated no graft-related complications and maintenance of growth capacity in TEVGs created using the closed apparatus. In addition, the use of the closed system reduced the amount of time needed to assemble the TEVG by ∼ 50%. Adaptation of similar methodologies may facilitate the safe translation and the widespread use of other tissue engineering technologies.

Citing Articles

Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.

Tan W, Boodagh P, Selvakumar P, Keyser S Front Bioeng Biotechnol. 2023; 10:1097334.

PMID: 36704297 PMC: 9871289. DOI: 10.3389/fbioe.2022.1097334.


Tissue engineered vascular grafts transform into autologous neovessels capable of native function and growth.

Blum K, Zbinden J, Ramachandra A, Lindsey S, Szafron J, Reinhardt J Commun Med (Lond). 2022; 2:3.

PMID: 35603301 PMC: 9053249. DOI: 10.1038/s43856-021-00063-7.


Development of a Semi-Automated, Bulk Seeding Device for Large Animal Model Implantation of Tissue Engineered Vascular Grafts.

Cunnane E, Lorentz K, Soletti L, Ramaswamy A, Chung T, Haskett D Front Bioeng Biotechnol. 2020; 8:597847.

PMID: 33195168 PMC: 7644804. DOI: 10.3389/fbioe.2020.597847.


Spontaneous reversal of stenosis in tissue-engineered vascular grafts.

Drews J, Pepper V, Best C, Szafron J, Cheatham J, Yates A Sci Transl Med. 2020; 12(537).

PMID: 32238576 PMC: 7478265. DOI: 10.1126/scitranslmed.aax6919.


Factors Influencing Poor Outcomes in Synthetic Tissue-Engineered Tracheal Replacement.

Pepper V, Best C, Buckley K, Schwartz C, Onwuka E, King N Otolaryngol Head Neck Surg. 2019; 161(3):458-467.

PMID: 31035858 PMC: 7202801. DOI: 10.1177/0194599819844754.


References
1.
Hibino N, McGillicuddy E, Matsumura G, Ichihara Y, Naito Y, Breuer C . Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg. 2010; 139(2):431-6, 436.e1-2. DOI: 10.1016/j.jtcvs.2009.09.057. View

2.
Hibino N, Shinoka T, Matsumura G, Ikada Y, Kurosawa H . The tissue-engineered vascular graft using bone marrow without culture. J Thorac Cardiovasc Surg. 2005; 129(5):1064-70. DOI: 10.1016/j.jtcvs.2004.10.030. View

3.
Mirensky T, Breuer C . The development of tissue-engineered grafts for reconstructive cardiothoracic surgical applications. Pediatr Res. 2008; 63(5):559-68. DOI: 10.1203/01.pdr.0000305938.92695.b9. View

4.
Duncan D, Breuer C . Challenges in translating vascular tissue engineering to the pediatric clinic. Vasc Cell. 2011; 3(1):23. PMC: 3205017. DOI: 10.1186/2045-824X-3-23. View

5.
Shinoka T, Matsumura G, Hibino N, Naito Y, Watanabe M, Konuma T . Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg. 2005; 129(6):1330-8. DOI: 10.1016/j.jtcvs.2004.12.047. View